AVEO Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on AVEO Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date AVEO Pharmaceuticals Inc Strategy Report
- Understand AVEO Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Business Description
AVEO Pharmaceuticals Inc (AVEO) discovers and develops products for the treatment of breast cancer, multiple myeloma, and lung cancer. It’s proprietary cancer biology platform with drug development and commercial expertise with its efforts to discover and develop targeted cancer therapeutics. The company's pipeline products include tivozanib, ficlatuzumab, AV-203, AV-380, and AV-353. Tivozanib is an oral tyrosine kinase inhibitor. It is a potent, selective long half-life inhibitor of all three vascular endothelial growth factor (VEGF) receptors. It is designed to optimize VEGF blockade and minimize off-target toxicities. The company seeks to commercialize tivozanib for the treatment of a wide range of cancers.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer